Clinical trials of psychedelics have mostly inferred what a dose is doing in the brain from what a patient reports feeling. A research program at Copenhagen’s Rigshospitalet is instead measuring it directly. Using simultaneous PET-MRI, the group is mapping the dose-occupancy relationship between LSD and the serotonin 2A receptor, the site through which classic psychedelics produce their effects, across a range of oral doses in living human brains. That is a more basic and more consequential kind of data than it sounds, because it is exactly the pharmacodynamic evidence that dose-selection for the entire lysergide drug-development effort has largely had to assume rather than see.
What the trial actually is
The program, known as DOCLS, is led by Gitte Moos Knudsen’s Neurobiology Research Unit, with Patrick Fisher and Drummond McCulloch, and is registered on ClinicalTrials.gov. It uses the PET radioligand CIMBI-36, developed by the same Copenhagen center specifically to image the serotonin 2A receptor, alongside simultaneous MRI, across oral LSD doses spanning roughly 25 to 200 micrograms. The design measures two things at once: how much of the receptor a given dose actually occupies, and what that occupancy does to cerebral blood flow. It is not a treatment trial. There is no depression or anxiety endpoint here. It is basic pharmacology, establishing the ground truth that clinical dosing decisions elsewhere are built on top of.
Why this is not old news, and also not entirely new
An interim analysis from this same trial infrastructure was posted to medRxiv in June 2025, reporting the first integration of molecular and functional neuroimaging during a psychedelic drug’s effects in humans, and quantifying LSD’s cerebral 5-HT2A occupancy for the first time. That preprint has since been updated, as recently as February 2026, with expanded dose-occupancy analysis from the same protocol. The trial itself remains active, with a primary completion date extending into 2027. So this is neither a brand-new study appearing out of nowhere, nor a stale one being recycled as news. It is an ongoing, multi-year research program that has already produced real, usable interim findings and continues to add to them, the kind of long-arc basic-science effort that rarely announces itself all at once and is easy to under-cover precisely because there is no single dramatic press release attached to it.
Why receptor occupancy is the missing piece
Every clinical psychedelic trial picks a dose. Almost none of them can say with precision what percentage of the target receptor that dose actually occupies in a given patient’s brain. Doses have historically been set by tradition, by early dose-ranging studies using subjective effects as the readout, or by simple extrapolation. Direct occupancy data changes that. It offers an objective, measurable anchor for what a given microgram amount is doing at the molecular level, independent of how a participant describes the experience, and it opens the door to asking sharper questions: whether a lower dose still engages the receptor enough to matter, whether occupancy plateaus at some point past which more drug adds side effects without more effect, and whether the relationship between occupancy and subjective intensity is as tight as trial designers have assumed.
Where this lands on the desk’s map
This connects directly to two threads already in motion. It is receptor-level ground truth for the field’s biggest open mechanistic question, whether the antidepressant effect of classic psychedelics tracks cleanly with 5-HT2A engagement or partly runs through other receptors, the same question this desk raised around psilocybin and 5-HT2B. And it bears immediately on Definium’s lysergide program, which has built its registrational strategy in major depression and anxiety around a 2:1:2 dosing design using a 50-microgram arm specifically intended to probe the line between an active and a barely perceptible dose. Direct occupancy data at doses spanning that exact range is precisely the kind of evidence that could validate, or complicate, the pharmacological logic behind that design. Whether the Copenhagen data and Definium’s clinical program ever formally connect is unknown, they are independent efforts, but the basic-science and the registrational tracks are now measuring adjacent things, and readers following the DT120 program have reason to watch the DOCLS work as context for how confident anyone can be about what a given lysergide dose is actually doing.
The caveats
This is healthy-volunteer, dose-ranging pharmacology, not a patient trial, and receptor occupancy is not the same as clinical effect; a dose can occupy a receptor without producing therapeutic benefit, and the relationship between occupancy and outcome remains to be established, not assumed. The published findings so far are interim, and the fullest dose-occupancy characterization is still to come as the trial completes. And this is one research group’s radioligand and methodology; independent replication with other tracers and cohorts would strengthen confidence in the specific occupancy figures. None of that diminishes the value of doing the measurement. It means the measurement is one input, an important one, rather than a final answer.
The frame
The psychedelic field has spent the last several years generating clinical outcome data faster than it has generated basic pharmacodynamic data to explain that data. A multi-year program directly measuring how LSD occupies its target receptor across a dose range is the unglamorous, slow-moving work that eventually underwrites or undermines the dosing assumptions built into every clinical program using the molecule, Definium’s included. It rarely makes headlines because it produces no single dramatic result, only an accumulating, increasingly precise picture. For a field whose biggest registrational bet is currently riding on a specific low-dose design for exactly this molecule, that accumulating picture is worth watching as closely as the next Phase 3 readout.